AstraZeneca plc (NYSE:AZN) Receives $50.35 Average PT from Analysts
Shares of AstraZeneca plc (NYSE:AZN) have been given a consensus rating of “Hold” by the fourteen research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $50.35.
Several equities research analysts have recently weighed in on the company. Svb Leerink assumed coverage on AstraZeneca in a research report on Friday, November 22nd. They issued an “outperform” rating for the company. Leerink Swann assumed coverage on AstraZeneca in a research report on Friday, November 22nd. They issued an “outperform” rating and a $57.00 target price for the company. ValuEngine raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, February 4th. Cowen reaffirmed an “outperform” rating and issued a $55.00 target price (up previously from $48.00) on shares of AstraZeneca in a research report on Monday, December 2nd. Finally, Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Thursday, October 24th.
A number of institutional investors and hedge funds have recently modified their holdings of AZN. Clear Harbor Asset Management LLC bought a new position in AstraZeneca during the 4th quarter worth approximately $25,000. Prime Capital Investment Advisors LLC bought a new position in AstraZeneca during the 3rd quarter worth approximately $34,000. Americana Partners LLC bought a new position in AstraZeneca during the 4th quarter worth approximately $37,000. Orion Portfolio Solutions LLC bought a new position in AstraZeneca during the 4th quarter worth approximately $39,000. Finally, Manchester Financial Inc. bought a new position in AstraZeneca during the 4th quarter worth approximately $42,000. 17.44% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca (NYSE:AZN) last issued its earnings results on Friday, February 14th. The company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.08). AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. The company had revenue of $6.66 billion during the quarter, compared to analysts’ expectations of $6.75 billion. During the same period in the previous year, the company earned $1.58 EPS. AstraZeneca’s quarterly revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts anticipate that AstraZeneca will post 2.09 earnings per share for the current year.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: How to calculate compound interest
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.